A novel anticoagulation system ( REG1 , Regado Biosciences ) , developed using a protein-binding oligonucleotide to factor IXa ( drug , RB006 ) and its complementary oligonucleotide antidote ( RB007 ) , was evaluated in healthy volunteers .
